First human trial targets 'Undruggable' cancer mutation
NCT ID NCT07417189
Summary
This study is testing a new oral drug called ABSK141 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to find a safe dose, see how the body processes the drug, and check if it can help control cancers like colorectal, lung, and pancreatic cancer. It is for adults whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 201321, China
Contact
Conditions
Explore the condition pages connected to this study.